BioSpace News Archive

The Government Accountability Office announced today that Abby Sears, president and chief executive officer of OCHIN, a national health technology nonprofit based in Portland, Oregon, has been appointed to the federal Health Information Technology Advisory Committee (HITAC)

In recognition of John Muir Health’s long-standing commitment to innovation and advancement of patient care, the health system’s Concord Medical Center has been designated as a Foregut Mentor Site for da Vinci® Xi Surgical System robotic procedures.

Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI), effective prior to market open on Monday, December 23, 2019.

CooperCompanies announced that it will hold its next annual meeting of stockholders on Wednesday, March 18, 2020.

bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will present at the following upcoming investor conferences in January

IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) is pleased to announce that it has filed a preliminary short form prospectus (the “Prospectus”) with respect to an offering (the “Offering”) of units (“Units”) for a minimum of Cdn$4,000,000 and a maximum of Cdn$10,000,000 aggregate gross proceeds

Trividia Health, Inc. and Mellitus Health, Inc. have partnered to develop solutions to help improve diabetes care through pharmacies and pharmacy-based clinics.

Orapeutic, the company’s third FDA cleared product, has been developed to fight the current opioid epidemic that the healthcare industry is facing today.

A live audio webcast of the presentation will be available on the Investor Relations section of R1’s website at r1rcm.com.

Filing for ABP 798 Supported by Two Comparative Clinical Studies